Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Aura Biosciences Inc

Healthcare US AURA

6.88USD
-0.02(0.29%)

Last update at 2026-06-03T20:00:00Z

Day Range

6.816.90
LowHigh

52 Week Range

4.347.48
LowHigh

Fundamentals

  • Previous Close 6.90
  • Market Cap452.26M
  • Volume252257
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-111.66200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.76

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -106.08300M -86.80700M -76.27100M -58.76300M -35.25100M
Minority interest - - - - -
Net income -106.19100M -86.91900M -76.40800M -57.23100M -34.42100M
Selling general administrative 22.49M 22.81M 19.76M 18.06M 10.09M
Selling and marketing expenses - - 19.74M - -
Gross profit - -1.22300M -1.29500M -60.29500M -35.25000M
Reconciled depreciation 1.13M 1.22M 1.29M 1.18M 0.83M
Ebit -112.79100M -96.11600M -84.99100M -60.29500M -35.25000M
Ebitda -111.66200M -94.89300M -83.69600M -59.96800M -35.23600M
Depreciation and amortization 1.13M 1.22M 1.29M 0.33M 0.01M
Non operating income net other - - - 1.53M -0.00100M
Operating income -112.79100M -96.11600M -84.99100M -60.29500M -35.25000M
Other operating expenses 112.79M 96.12M 84.99M 60.30M 35.25M
Interest expense - - - 0.85M 0.01M
Tax provision 0.11M 0.11M 0.14M - -
Interest income 6.63M 9.43M 7.04M 1.86M -
Net interest income 6.63M 9.43M 7.04M 1.86M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.11M 0.11M 0.14M -1.53200M -0.83000M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 112.79M 96.12M 83.70M 60.30M 35.25M
Cost of revenue - 1.22M 1.29M 60.30M 35.25M
Total other income expense net 6.71M 9.31M 8.72M 1.53M -0.00100M
Discontinued operations - - - - -
Net income from continuing ops -106.19100M -86.91900M -70.83600M -58.76300M -35.25100M
Net income applicable to common shares - - - -58.76300M -35.25100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 169.43M 182.50M 255.07M 223.94M 160.03M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.50M 9.53M 5.62M 7.87M 4.62M
Total liab 32.52M 30.53M 29.23M 28.35M 7.71M
Total stockholder equity 136.91M 151.97M 225.85M 195.58M 152.31M
Deferred long term liab - - - - -
Other current liab 13.59M 9.46M 7.88M 4.57M 0.42M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -480.41800M -374.22700M -287.30800M -210.90000M -152.13700M
Other liab - - - - 0.08M
Good will - - - - -
Other assets - - 0.00000M 1.19M 0.12M
Cash 59.52M 31.69M 41.08M 121.58M 149.06M
Cash and equivalents - - - - -
Total current liabilities 18.38M 14.91M 12.36M 10.46M 7.27M
Current deferred revenue - - - - 3.83M
Net debt -42.13800M -12.92400M -21.52500M -100.72400M -148.08800M
Short term debt 3.24M 3.15M 2.69M 2.96M 0.61M
Short long term debt - - - - -
Short long term debt total 17.38M 18.77M 19.56M 20.86M 0.97M
Other stockholder equity 617.43M 525.93M 512.62M 406.56M 144.42M
Property plant equipment - - - 5.37M 5.25M
Total current assets 149.74M 160.62M 231.79M 196.70M 153.70M
Long term investments - - - - -
Net tangible assets - - - 195.58M 152.31M
Short term investments 84.73M 119.40M 185.09M 67.23M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.55M 2.30M 1.79M 2.92M 2.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10200M 0.26M 0.54M -0.07200M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -210.90000M -152.13700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.24M 1.29M 0.51M 1.19M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 19.69M 21.88M 23.28M 27.23M 6.33M
Capital lease obligations 17.38M 18.77M 19.56M 20.86M 0.97M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 36.04M 68.82M -40.71900M -66.77500M -2.12500M
Change to liabilities - - - 0.57M 3.26M
Total cashflows from investing activities 35.59M 68.82M -113.96300M -67.86900M -2.12500M
Net borrowings - - - - -
Total cash from financing activities 77.16M 1.59M 97.29M 95.63M 166.26M
Change to operating activities - - - -3.44200M -1.36900M
Net income -106.19100M -86.91900M -76.40800M -58.76300M -35.25100M
Change in cash 27.82M -9.38900M -80.52000M -26.84100M 131.72M
Begin period cash flow 32.46M 41.85M 122.37M 149.21M 17.49M
End period cash flow 60.28M 32.46M 41.85M 122.37M 149.21M
Total cash from operating activities -84.74200M -79.80500M -63.84700M -54.60100M -32.41000M
Issuance of capital stock 52.57M 0.00000M 98.37M 95.20M 165.93M
Depreciation 1.13M 1.22M 1.29M 1.18M 0.83M
Other cashflows from investing activities - -0.00500M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 87.08M 166.27M
Other cashflows from financing activities 77.16M 1.59M 94.12M 87.08M 87.56M
Change to netincome - - - 6.09M 2.32M
Capital expenditures 0.45M 1.25M 0.71M 1.09M 2.12M
Change receivables - - - - -
Cash flows other operating - - - -3.67600M -3.57100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -26.84100M 131.72M
Change in working capital 5.97M -2.64200M 4.44M -3.10200M -0.31500M
Stock based compensation 14.32M 11.72M 8.77M 6.41M 2.31M
Other non cash items 0.03M -3.18900M -1.94700M -0.32500M 0.00400M
Free cash flow -85.18900M -81.05800M -64.55600M -55.69500M -34.53500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AURA
Aura Biosciences Inc		 -0.02 0.29% 6.88 - - - 3.31 -5.6773
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Aura Biosciences Inc

80 Guest Street, Boston, MA, United States, 02135

Key Executives

Name Title Year Born
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, Pres & Director 1974
Ms. Julie B. Feder CFO, Sec. & Treasurer 1970
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA Chief Medical Officer and Head of R&D 1965
Dr. Mark A. De Rosch Ph.D. Chief Operating Officer 1964
Mr. Paulo Carvalho VP of Technical Operations NA
Mr. Joseph Lyons VP of HR NA
Ms. Michele Keough M.B.A. Sr. VP of Project Management and Device Supply Chain NA
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 1973
Ms. Julie B. Feder CFO, Secretary & Treasurer 1970
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.